Pivotal, Clinical Study for the Accuracy Evaluation of the IdentiClone Dx TRG Assay

Not yet recruitingOBSERVATIONAL
Enrollment

250

Participants

Timeline

Start Date

June 2, 2025

Primary Completion Date

November 6, 2025

Study Completion Date

December 6, 2025

Conditions
T-Cell Lymphoproliferative Disorder
Interventions
DIAGNOSTIC_TEST

IdentiClone Dx TRG Assay

"The IdentiClone Dx TRG Assay (Assay) is an in vitro diagnostic product intended for qualitative capillary electrophoresis based-detection of clonality in T-cell receptor gamma chain (TRG) gene rearrangements in Formalin-Fixed Paraffin-Embedded (FFPE) specimens as an adjunctive method for the diagnosis of T-cell lymphoproliferative disease. This qualitative, non-automated Assay is for use on the ABI 3500xL Dx and ABI 3500xL Genetic Analyzers."

Trial Locations (3)

85399

LabPMM GmbH, Hallbergmoos

92103

Invivoscribe, Inc., San Diego

210-0821

LabPMM GK, Kawasaki-shi

All Listed Sponsors
lead

Invivoscribe, Inc.

INDUSTRY

NCT06876571 - Pivotal, Clinical Study for the Accuracy Evaluation of the IdentiClone Dx TRG Assay | Biotech Hunter | Biotech Hunter